J Exp Med

J Exp Med Selleckchem Belnacasan 2002, 195:415–422.PubMedCrossRef 18. Zhong W, Gern L, Stehle T, Museteanu C, Kramer M, Wallich R, Simon MM: Resolution of experimental and tick-borne Borrelia burgdorferi infection in mice by passive, but not active immunization using recombinant OspC. Eur J Immunol 1999, 29:946–957.PubMedCrossRef 19. Hodzic E, Feng S, Freet KJ, Borjesson

DL, Barthold SW: Borrelia burgdorferi population kinetics and selected gene expression at the host-vector interface. Infect Immun 2002, 70:3382–3388.PubMedCrossRef 20. Salazar CA, Rothemich M, Drouin EE, Glickstein L, Steere AC: Human Lyme arthritis and the immunoglobulin G antibody response to the 37-kilodalton arthritis-related protein of Borrelia burgdorferi . Infect Immun 2005, 73:2951–2957.PubMedCrossRef 21. Tunev SS, Hastey CJ, Hodzic E, Feng S, Barthold SW, Baumgarth N: Lymphadenopathy during Lyme borreliosis is caused by spirochete migration- induced specific B cell activation. PLoS Pathog 2011, 7:e1002066.PubMedCrossRef 22. Hodzic E, Feng S, Freet K, Barthold SW: Borrelia burgdorferi population dynamics and prototype gene expression during infection of immunocompetent and immunodeficient mice. Infect Immun 2003, 71:5042–5055.PubMedCrossRef 23. Liang FT, Yan J, Mbow ML, Sviat SL, Gilmore RD, Mamula M, Fikrig E: Borrelia burgdorferi changes its surface antigenic expression in response to host immune responses. Infect Immun 2004, see more 72:5759–5767.PubMedCrossRef

24. Probert WS, LeFebvre RB: Protection of C3H/HeN mice from challenge with Borrelia burgdorferi through active immunization with OspA, OspB, or OspC, but not with OspD or the 83-kilodalton

antigen. Infect Immun 1994, 62:1920–1926.PubMed 25. Bankhead T, Chaconas G: The role of VlsE antigenic variation in the Lyme disease spirochete: persistence through a mechanism that differs from other pathogens. Mol Microbiol 2007, 65:1547–1558.PubMedCrossRef 26. Labandeira-Rey M, Seshu J, Skare J: The absence of linear plasmid 25 or 28–1 of Borrelia burgdorferi dramatically alters the kinetics of experimental infection via distinct mechanisms. Infect Immun 2003, 71:4608–4613.PubMedCrossRef 27. Labandeira-Rey M, Skare JT: Decreased infectivity in Borrelia burgdorferi strain B31 is associated with 17-DMAG (Alvespimycin) HCl loss of linear plasmid 25 or 28–1. Infect Immun 2001, 69:446–455.PubMedCrossRef 28. Purser JE, Norris SJ: Correlation between plasmid content and infectivity of Borrelia burgdorferi . Proc Natl Acad Sci USA 2000, 97:13865–13870.PubMedCrossRef 29. Xu Q, Seemanapalli SV, Lomax L, McShan K, Li X, Fikrig E, Liang FT: Association of linear plasmid 28–1 with an arthritic phenotype of Borrelia burgdorferi . Infect Immun 2005, 73:7208–7215.PubMedCrossRef 30. Pal U, Wang P, Bao F, Yang X, Samanta S, Schoen R, Wormser GP, Schwartz I, Fikrig E: Borrelia burgdorferi basic membrane proteins A and B participate in the genesis of Lyme arthritis. J Exp Med 2008, 205:133–141.PubMedCrossRef 31.

Comments are closed.